Orgenesis Stock Financials

ORGS -  USA Stock  

USD 4.78  0.13  2.65%

Understanding current and past Orgenesis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Orgenesis' financial statements are interrelated, with each one affecting the others. For example, an increase in Orgenesis' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Orgenesis' financials over time to get the whole picture.
Please use analysis of Orgenesis fundamentals to determine if markets are correctly pricing the firm. We were able to analyze and collect data for thirty-four available financial ratios for Orgenesis, which can be compared to its competitors. To make sure the equity is not overpriced, please check all Orgenesis financials, including its price to book, current ratio, working capital, as well as the relationship between the net income and number of employees . Given that Orgenesis has a price to earning of 16.56 X, we recommend you to check out Orgenesis recent market performance to make sure the company can sustain itself down the road. Use Orgenesis to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Orgenesis to be traded at $4.59 in 90 days.

Search Fundamentals 

 
Refresh
With this module, you can analyze Orgenesis financials for your investing period. You should be able to track the changes in Orgenesis individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Over 90
Orgenesis has more than 90 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Orgenesis stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Orgenesis' official financial statements usually reflect Orgenesis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Orgenesis. For example, before you start analyzing numbers published by Orgenesis accountants, it's critical to develop an understanding of what Orgenesis' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Orgenesis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orgenesis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Orgenesis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orgenesis. Please utilize our Beneish M Score to check the likelihood of Orgenesis' management to manipulate its earnings.

Orgenesis Company Summary

Orgenesis competes with Wuxi Biologics, Regeneron Pharmaceuticals, Vertex Pharmaceutic, Seagen, and Beigene. Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business Address20271 Goldenrod Lane
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.orgenesis.com
Phone480 659 6404
CurrencyUSD - US Dollar

Orgenesis Key Financial Ratios

Generally speaking, Orgenesis' financial ratios allow both analysts and investors to convert raw data from Orgenesis' financial statements into concise, actionable information that can be used to evaluate the performance of Orgenesis over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Orgenesis reports annually and quarterly.

Orgenesis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Orgenesis's current stock value. Our valuation model uses many indicators to compare Orgenesis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orgenesis competition to find correlations between indicators driving Orgenesis's intrinsic value. More Info.
Orgenesis is rated below average in price to sales category among related companies. It is regarded second in beta category among related companies totaling about  0.15  of Beta per Price to Sales. The ratio of Price to Sales to Beta for Orgenesis is roughly  6.66 

Orgenesis Systematic Risk

Orgenesis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Orgenesis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Orgenesis correlated with the market. If Beta is less than 0 Orgenesis generally moves in the opposite direction as compared to the market. If Orgenesis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Orgenesis is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Orgenesis is generally in the same direction as the market. If Beta > 1 Orgenesis moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Orgenesis Financials

What exactly are Orgenesis Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Orgenesis' income statement, its balance sheet, and the statement of cash flows. Potential Orgenesis investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Orgenesis investors may use each financial statement separately, they are all related. The changes in Orgenesis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Orgenesis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Orgenesis July 28, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Orgenesis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Orgenesis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Orgenesis based on widely used predictive technical indicators. In general, we focus on analyzing Orgenesis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Orgenesis's daily price indicators and compare them against related drivers.
Downside Deviation4.14
Information Ratio(0.005152)
Maximum Drawdown37.65
Value At Risk(7.51)
Potential Upside8.79
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.